Canadian Association of Optometrists Marks Vision Health Month with “GetEyeWise” Digital Awareness Campaign The Canadian Association of Optometrists is once again placing eye health in the national spotlight through its annual public education initiative, encouraging Canadians to take a closer…
Agendia to Showcase New Evidence Supporting Expanded Use of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Congress Agendia Inc., a leader in genomic testing for breast cancer, has announced the presentation of new clinical data at the European…
Corcept’s Phase 2 Trial of Dazucorilant Shows Sustained Two-Year Survival Advantage in ALS Patients Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage biopharmaceutical company focused on developing therapies that modulate cortisol activity, has reported new long-term data from its Phase 2…
U.S. FDA Accepts Priority Review for Gilead’s Once-Daily HIV Therapy Combining Bictegravir and Lenacapavir Gilead Sciences has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for an investigational once-daily, single-tablet regimen combining…
Study Reveals Growing Public Optimism for Scientific Breakthroughs Amid Increasing Concerns Over the Pace of Global Change A new global report developed by Leaps by Bayer in collaboration with Boston Consulting Group and Ipsos UK sheds fresh light on how…
Samsung Bioepis and ATLATL Enter MoU to Advance Early-Stage Biotech Innovation Across Asia-Pacific Samsung Bioepis Co., Ltd. has entered into a strategic collaboration with ATLATL Innovation Center to strengthen early-stage biotechnology innovation across the Asia-Pacific region. The two organizations announced…
Genexine’s First-in-Class SOX2 Degrader GX-BP1 Achieves Up to 96% Tumor Growth Inhibition and Prevents Regrowth in Preclinical Studies Genexine, Inc., a clinical-stage biotechnology firm focused on next-generation therapeutic platforms, has reported new preclinical findings for its innovative oncology candidate GX-BP1.…
Advancing Limb Salvage: Cagent Vascular Reports Landmark Peer-Reviewed Evidence Supporting Serration Remodeling Therapy™ in Complex Below-the-Ankle Arteries Cagent Vascular, a recognized innovator in endovascular device technologies, has announced the publication of new peer-reviewed clinical evidence in the Journal of Endovascular…
Mirai Bio to Debut Two Next-Generation Programs for Extrahepatic Targeted Nucleic Acid Delivery at the ASGCT 2026 Annual Meeting Mirai Bio, a company focused on enabling the next generation of nucleic acid therapeutics through advanced delivery technologies, has announced its…
Pixee Medical Secures U.S. Food and Drug Administration 510(k) Clearance for Next-Generation Knee+ NexSight on Advanced Augmented Reality Platform Pixee Medical, a recognized innovator in augmented reality (AR) navigation for orthopedic procedures, has achieved a significant regulatory milestone with the…
Sunnybrook Receives $41 Million Donation to Strengthen Canada’s Global Leadership in Clinical Trials Sunnybrook Health Sciences Centre has announced a transformative $41 million philanthropic investment aimed at reshaping the future of clinical research through the expansion of Sunnybrook Clinical Trials.…
Arrowhead Pharmaceuticals Secures Positive CHMP Recommendation for REDEMPLO® (plozasiran) to Treat Elevated Triglycerides in Adults with Familial Chylomicronemia Syndrome in Europe Arrowhead Pharmaceuticals has taken a significant step forward in advancing treatment options for patients living with the rare and…